《Avidity Biosciences, Inc. (RNA) 2025年第一季度财报(10-Q)「NASDAQ」.pdf》由会员分享,可在线阅读,更多相关《Avidity Biosciences, Inc. (RNA) 2025年第一季度财报(10-Q)「NASDAQ」.pdf(36页珍藏版)》请在三个皮匠报告上搜索。
1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549_FORM 10-Q_xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934FOR THE QUARTERLY PERIOD ENDED MARCH 31,2025oroTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHA
2、NGE ACT OF1934Commission File Number 001-39321_Avidity Biosciences,Inc.(Exact name of registrant as specified in its charter)_Delaware46-1336960(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.)10578 Science Center Drive,Suite 125San Diego,California92121(A
3、ddress of principal executive offices)(Zip Code)(858)401-7900(Registrants telephone number,including area code)_Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock,$0.0001 par valueRNAThe Nasdaq Global Ma
4、rketIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)ofthe Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant wasrequired to file such reports),and(2)has been subject to such fi
5、ling requirements for the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required tobe submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or forsuch shorter period that
6、 the registrant was required to submit such files).Yes x No oIndicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-acceleratedfiler,a smaller reporting company or an emerging growth company.See the definitions of“large accelerated filer,”“accelerated f